Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790MKenneth S. Thress, Geoffrey R. Oxnard, Dalia Ercan et al.|Nature Medicine|2015Cited by 1.5k
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung CancerGeoffrey R. Oxnard, Pasi A. Jänne, Kenneth S. Thress et al.|Journal of Clinical Oncology|2016Cited by 843
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to OsimertinibGeoffrey R. Oxnard, Pasi A. Jänne, Yuebi Hu et al.|JAMA Oncology|2018Cited by 689
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerGeoffrey R. Oxnard, Myung‐Ju Ahn, J.C.-H. Yang et al.|Annals of Oncology|2020Cited by 443
385TiP AZD0901 monotherapy in patients (pts) with advanced biliary tract cancer (BTC) expressing claudin18.2 (CLDN18.2): CLARITY-PanTumour01 substudy 3Love Goyal, Ali Raufi, Yelena Y. Janjigian et al.|Annals of Oncology|2025Cited by 1